Table 4.

Overall survival (OS) of patients with NSCLC brain metastases treated with first-generation and third-generation EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs) in the first line and 2nd-to-5th line treatment settings. NA: Not Available.

Therapy	EGFR-TKI	Median OS (Months)	1-Year OS (95% CI)	2-Year OS (95% CI)
1st line	erlotinib/gefitinib	18.2	63% (48%, 75%)	32% (19%, 46%)
	Osimertinib	19.4	82% (63%, 92%)	36% (13%, 61%)
2nd–5th line	erlotinib/gefitinib	17.3	NA	NA
	Osimertinib	11.9	NA	NA